Critical Reviews in Oral Biology & Medicine, Vol 4, 455-459, Copyright © 1993 by International & American Associations for Dental Research

ARTICLES

Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus

M. R. Robinovitch, J. M. Iversen and L. Resnick
Department of Oral Biology, School of Dentistry University of Washington, Seattle 98195.

The purpose of this investigation was to adapt an MT-2 cell syncytium-forming assay for measuring anti-infectivity activity of salivary secretions toward HIV and to determine the distribution of this activity in a population of healthy adult subjects. Whole saliva samples were collected from 27 volunteers, who reported that they did not belong to any group at high risk for HIV infection, and tested for anti-infectivity activity using the syncytium-forming assay. Nine of these subjects were subsequently retested on one or more occasions to assess the variability in appearance of this activity. Parotid and extraparotid salivas of six subjects were also tested. Samples were frozen immediately after collection and submitted in blinded fashion for quantitation of their anti-HIV activity using a syncytia-forming MT-2 cell assay or the p24 antigen ELISA. Nine out of the 27 subjects showed detectable anti-HIV infectivity activity. One parotid sample and one extraparotid sample out of four from subjects with positive whole salivas were positive and none of the parotid or extraparotid samples from two subjects with negative whole salivas were positive. The inhibitory activity ranged from 0.5 to 1 log 10 TCID50/ml and could not be correlated with total protein content in saliva or any specific electrophoretic component. Filtration of the saliva through an Amicon 10 filter before incubation with the virus abolished the activity. Similar studies using two other biological fluids, urine and cerebrospinal fluid, revealed no anti-HIV infectivity activity. These findings confirm the presence in saliva of inhibitory activity directed toward HIV.

This article has been cited by other articles:

				X. Liu, J. Zha, H. Chen, J. Nishitani, P. Camargo, S. W. Cole, and J. A. Zack Human Immunodeficiency Virus Type 1 Infection and Replication in Normal Human Oral Keratinocytes J. Virol., March 15, 2003; 77(6): 3470 - 3476. [Abstract] [Full Text] [PDF]

				K. Ikuta, S. Suzuki, H. Horikoshi, T. Mukai, and R. B. Luftig Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis Microbiol. Mol. Biol. Rev., December 1, 2000; 64(4): 725 - 745. [Abstract] [Full Text] [PDF]

				A. A. M. A. Baqui, T. F. Meiller, and W. A. Falkler Jr. Enhanced Secretory Leukocyte Protease Inhibitor in Human Immunodeficiency Virus Type 1-Infected Patients Clin. Vaccine Immunol., November 1, 1999; 6(6): 808 - 811. [Abstract] [Full Text] [PDF]

				S. Baron, J. Poast, and M. W. Cloyd Why Is HIV Rarely Transmitted by Oral Secretions?: Saliva Can Disrupt Orally Shed, Infected Leukocytes Arch Intern Med, February 8, 1999; 159(3): 303 - 310. [Abstract] [Full Text] [PDF]

				T. B. McNeely, D. C. Shugars, M. Rosendahl, C. Tucker, S. P. Eisenberg, and S. M. Wahl Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by Secretory Leukocyte Protease Inhibitor Occurs Prior to Viral Reverse Transcription Blood, August 1, 1997; 90(3): 1141 - 1149. [Abstract] [Full Text] [PDF]